Literature DB >> 1400198

Generation of lipooligosaccharide mutants of Haemophilus influenzae type b.

R McLaughlin1, S M Spinola, M A Apicella.   

Abstract

We previously reported the analysis of recombinant plasmids from Haemophilus influenzae type b (Hib) that lead to modifications of Escherichia coli lipopolysaccharide (LPS) (Y. Abu Kwaik, R. E. McLaughlin, M. A. Apicella, and S. M. Spinola, Mol. Microbiol. 5:2475-2480, 1991). The modified LPS species are recognized by monoclonal antibodies (MAbs) 6E4 and 3F11. MAb 6E4 binds to a stable 2-keto-3-deoxyoctulosonic acid epitope, while MAb 3F11 binds to a Gal beta 1-4GlcNac epitope that phase varies in Hib at a frequency of 2 to 5%. The internal EcoRI fragment containing most of the DNA required for LPS modification in E. coli was used as the target for transposon mutagenesis. Plasmids containing minitransposon m-Tn3(Cm) randomly inserted into the target fragment were transformed into the isogenic Hib strain, and transposon integration into the Hib chromosome was verified by colony hybridization. The lipooligosaccharides of 36 transformants were phenotypically and antigenically characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and reactivity with a variety of MAbs that recognize both stable and phase-varying lipooligosaccharide epitopes. The majority of the mutants had altered reactivity with MAb 6E4. With one exception, these mutants retained the ability to express phase-varying epitopes. Analysis of the transformants suggested that the 6E4 epitope was contained on an oligosaccharide chain separate from that of phase-varying epitopes and appeared to be assembled in at least three separate steps.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400198      PMCID: PMC207602          DOI: 10.1128/jb.174.20.6455-6459.1992

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  22 in total

1.  Molecular analysis of a complex locus from Haemophilus influenzae involved in phase-variable lipopolysaccharide biosynthesis.

Authors:  D J Maskell; M J Szabo; P D Butler; A E Williams; E R Moxon
Journal:  Mol Microbiol       Date:  1991-05       Impact factor: 3.501

2.  Analysis of Haemophilus influenzae type b lipooligosaccharide-synthesis genes that assemble or expose a 2-keto-3-deoxyoctulosonic acid epitope.

Authors:  Y Abu Kwaik; R E McLaughlin; M A Apicella; S M Spinola
Journal:  Mol Microbiol       Date:  1991-10       Impact factor: 3.501

3.  The molecular mechanism of phase variation of H. influenzae lipopolysaccharide.

Authors:  J N Weiser; J M Love; E R Moxon
Journal:  Cell       Date:  1989-11-17       Impact factor: 41.582

4.  Contribution of lipopolysaccharide to pathogenicity of Haemophilus influenzae: comparative virulence of genetically-related strains in rats.

Authors:  A Zwahlen; L G Rubin; E R Moxon
Journal:  Microb Pathog       Date:  1986-10       Impact factor: 3.738

5.  Identification of phosphorylated 3-deoxy-manno-octulosonic acid as a component of Haemophilus influenzae lipopolysaccharide.

Authors:  S E Zamze; M A Ferguson; E R Moxon; R A Dwek; T W Rademacher
Journal:  Biochem J       Date:  1987-07-15       Impact factor: 3.857

6.  Identification of a chromosomal locus for expression of lipopolysaccharide epitopes in Haemophilus influenzae.

Authors:  J N Weiser; A A Lindberg; E J Manning; E J Hansen; E R Moxon
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

7.  Transposon mutagenesis and complementation of the fructokinase gene in Rhizobium leguminosarum biovar trifolii.

Authors:  R E McLaughlin; T A Hughes
Journal:  J Gen Microbiol       Date:  1989-08

8.  Haemophilus influenzae type b lipooligosaccharide: stability of expression and association with virulence.

Authors:  A Kimura; C C Patrick; E E Miller; L D Cope; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

9.  Composition of the lipopolysaccharide from different capsular serotype strains of Haemophilus influenzae.

Authors:  S E Zamze; E R Moxon
Journal:  J Gen Microbiol       Date:  1987-06

10.  Antigenic and phenotypic variations of Haemophilus influenzae type b lipopolysaccharide and their relationship to virulence.

Authors:  A Kimura; E J Hansen
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

View more
  6 in total

1.  Molecular cloning and characterization of the nontypeable Haemophilus influenzae 2019 rfaE gene required for lipopolysaccharide biosynthesis.

Authors:  N G Lee; M G Sunshine; M A Apicella
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

2.  Non-typeable Haemophilus influenzae protects human airway epithelial cells from a subsequent respiratory syncytial virus challenge.

Authors:  Stacey M Hartwig; Margaret Ketterer; Michael A Apicella; Steven M Varga
Journal:  Virology       Date:  2016-08-27       Impact factor: 3.616

3.  Adjacent and divergently oriented operons under the control of the sporulation regulatory protein GerE in Bacillus subtilis.

Authors:  S Roels; R Losick
Journal:  J Bacteriol       Date:  1995-11       Impact factor: 3.490

4.  Relative contributions of lipooligosaccharide inner and outer core modifications to nontypeable Haemophilus influenzae pathogenesis.

Authors:  Pau Morey; Cristina Viadas; Begoña Euba; Derek W Hood; Montserrat Barberán; Carmen Gil; María Jesús Grilló; José Antonio Bengoechea; Junkal Garmendia
Journal:  Infect Immun       Date:  2013-08-26       Impact factor: 3.441

5.  Mutational analysis of genes of the mod locus involved in molybdenum transport, homeostasis, and processing in Azotobacter vinelandii.

Authors:  N J Mouncey; L A Mitchenall; R N Pau
Journal:  J Bacteriol       Date:  1995-09       Impact factor: 3.490

6.  Nontypeable Haemophilus influenzae Lipooligosaccharide Expresses a Terminal Ketodeoxyoctanoate In Vivo, Which Can Be Used as a Target for Bactericidal Antibody.

Authors:  Michael A Apicella; Jeremy Coffin; Margaret Ketterer; Deborah M B Post; Christopher J Day; Freda E-C Jen; Michael P Jennings
Journal:  MBio       Date:  2018-07-31       Impact factor: 7.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.